Quarterly Result14 May 2026, 07:51 pm
Alivus Life Sciences: FY26 Revenue ₹25,518 Mn, PAT ₹5,644 Mn
AI Summary
Alivus Life Sciences Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹25,518.32 million and a profit after tax of ₹5,644.83 million for the year ended March 31, 2026. The board also recommended a final equity dividend of ₹5 (250%) per equity share of ₹2 each, subject to shareholder approval. The meeting concluded at 6.15 p.m.
Key Highlights
- Alivus Life Sciences' FY26 revenue from operations reached ₹25,518.32 million.
- The company's profit after tax (PAT) for FY26 stood at ₹5,644.83 million.
- A final equity dividend of ₹5 per share (250% on face value of ₹2) was recommended for FY26.
- The Board meeting to approve results and dividend occurred on May 14, 2026.
- Basic earnings per share for FY26 is ₹45.99.